157 related articles for article (PubMed ID: 12469657)
1. Make clinical research top priority.
Prophet S
J AHIMA; 2002 Jan; 73(1):19-20. PubMed ID: 12469657
[No Abstract] [Full Text] [Related]
2. Improving protection for research subjects.
Steinbrook R
N Engl J Med; 2002 May; 346(18):1425-30. PubMed ID: 11986426
[No Abstract] [Full Text] [Related]
3. Recruiting human subjects without IRB review/approval.
Maloney DM
Hum Res Rep; 2002 Aug; 17(8):3. PubMed ID: 12731493
[No Abstract] [Full Text] [Related]
4. US clinical-research system in need of review.
Ammann AJ
Nature; 2013 Jun; 498(7452):7. PubMed ID: 23739388
[No Abstract] [Full Text] [Related]
5. Protecting research subjects--what must be done.
Shalala D
N Engl J Med; 2000 Sep; 343(11):808-10. PubMed ID: 10984573
[No Abstract] [Full Text] [Related]
6. The impact of escalating regulatory requirements on the conduct of clinical research.
Gordon BG; Kessinger A; Mann SL; Prentice ED
Cytotherapy; 2003; 5(4):309-13. PubMed ID: 12944237
[TBL] [Abstract][Full Text] [Related]
7. Federal human research oversight of clinical trials in the United States.
Zarin DA; Tse T; Menikoff J
JAMA; 2014 Mar; 311(9):960-1. PubMed ID: 24595782
[No Abstract] [Full Text] [Related]
8. The letter or the spirit. Consent for research in CPR.
Olson CM
JAMA; 1994 May; 271(18):1445-7. PubMed ID: 8176805
[No Abstract] [Full Text] [Related]
9. Time for new rules on human subjects research?
Dresser R
Hastings Cent Rep; 1998; 28(6):23-4. PubMed ID: 9868606
[No Abstract] [Full Text] [Related]
10. Trials and errors: barriers to oversight of research conducted under the emergency research consent waiver.
Kipnis K; King NM; Nelson RM
IRB; 2006; 28(2):16-9. PubMed ID: 16770884
[No Abstract] [Full Text] [Related]
11. Continued concern: human subject protection, the institutional review board, and continuing review.
Hoffman S
Tenn Law Rev; 2001; 68(4):725-70. PubMed ID: 16189912
[No Abstract] [Full Text] [Related]
12. Protection of research subjects.
Tremaine WJ
N Engl J Med; 2003 Jul; 349(2):188-92; author reply 188-92. PubMed ID: 12856652
[No Abstract] [Full Text] [Related]
13. The Foreign Corrupt Practices Act and and clinical trials: a trap for the unwary.
Harker DA; Miller CE
Food Drug Law J; 2008; 63(2):509-23. PubMed ID: 18561475
[No Abstract] [Full Text] [Related]
14. Impact of cancer research bureaucracy on innovation, costs, and patient care.
Steensma DP; Kantarjian HM
J Clin Oncol; 2014 Feb; 32(5):376-8. PubMed ID: 24395852
[No Abstract] [Full Text] [Related]
15. Trial design and patient safety--the debate continues.
Steinbrook R
N Engl J Med; 2003 Aug; 349(7):629-30. PubMed ID: 12917298
[No Abstract] [Full Text] [Related]
16. Biotech and pharma face more costly clinical trials.
Brower V
Nat Biotechnol; 1998 Aug; 16(8):714. PubMed ID: 9702762
[No Abstract] [Full Text] [Related]
17. Cancer clinical trials: what is the impact of regulatory changes?
Kearsey L
ONS News; 2002 Sep; 17(9):1, 4-5. PubMed ID: 12244866
[No Abstract] [Full Text] [Related]
18. Research infrastructure and IRB/FDA requirements.
Cohen J
Med Health R I; 2000 Dec; 83(12):382-5. PubMed ID: 11190124
[No Abstract] [Full Text] [Related]
19. Ethical and regulatory challenges in advancing prehospital research: focus on sepsis.
Polito CC; Sevransky JE; Dickert NW
Am J Emerg Med; 2016 Mar; 34(3):623-5. PubMed ID: 26851062
[No Abstract] [Full Text] [Related]
20. Financial conflicts of interest and protection of human research subjects.
Maloney DM
Hum Res Rep; 2004 Jun; 19(6):1-2. PubMed ID: 15462034
[No Abstract] [Full Text] [Related]
[Next] [New Search]
